CONGRESS PRESENTATIONS
HIV Drug Therapy Glasgow 2024
November 10-13, 2024
Glasgow, Scotland
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Adelakun A, et al.
Cost‐effectiveness and public‐health impact of cabotegravir long‐acting injectable for HIV pre‐exposure prophylaxis in Canada
Cambiano V, et al.
Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre‐exposure prophylaxis in Europe: the PrEPaRe study
-
Cabotegravir Treatment
LaForty C, et al.
Real‐world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support programme in Canada, preliminary results
Thornhill J, et al.
Similar virological outcomes and frequency of isolated viraemic events (blips, low‐level viraemia and suspected virological failure) between oral and long‐acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long‐acting studies
-
Dolutegravir-based Regimens
Allavena C, et al.
Real world experience of DTG+3TC regimen: results from the French Dat'AIDS cohort (2015‐2022)
Basova A, et al.
Two‐year long‐term data on the efficacy and tolerability of dolutegravir‐based regimens from the prospective multi‐centre TESLA cohort study in ART‐naïve and pre‐treated people living with HIV in Russia
Basova A, et al.
The analysis of metabolic parameters in people living with HIV using dolutegravir‐based regimens in routine clinical practice in Russia
Fox D, et al.
Treatment‐emergent integrase strand transfer inhibitor (INSTI) resistance‐associated mutations among people living with HIV‐1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre‐existing M184V/I from real‐world and interventional studies
Kowalska J, et al.
A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE‐NEAT ID Network study
Lackey P, et al.
Incident hypertension with antiretroviral therapy: real‐world evidence from the OPERA cohort
Philibert P, et al.
CARAVEL: evaluation of real‐world effectiveness and sustainability of the two‐drug regimen dolutegravir/lamivudine fixed‐dose combination in treatment‐naive adults and pre‐treated adults who are virologically suppressed, in routine clinical care, in France: 2‐year interim analysis results
Sconza R, et al.
Outcomes following prenatal exposure to DTG‐containing antiretroviral therapy regimens: data from the DOLOMITE‐EPPICC study
Slim J, et al.
PAIRED ‐PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub‐analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States
Tusch E, et al.
Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia
Van Dam C, et al.
An EYEWITNESS to successful diversity in antiretroviral switch studies
-
Fostemsavir
Castagna A, et al.
Similar efficacy, safety and CD4 T‐cell increase up to week 96 observed with fostemsavir (FTR)‐based regimens in the BRIGHTE study and dolutegravir (DTG)‐based regimens in the VIKING‐3 study in individuals with multidrug‐resistant (MDR) HIV‐1
Spagnuolo V, et al.
CD4 T‐cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with lowlevel viraemia (LLV) up to week 192 with fostemsavir (FTR)‐based regimens in individuals with multidrug‐resistant (MDR) HIV‐1
-
Pipeline
Gartland M, et al.
Correlation of baseline phenotypic sensitivity with virological response to VH3810109 (N6LS) in BANNER
Keegan M, et al.
VH3810109 (N6LS) administration dose‐responsively enhances anti‐HIV antibody‐dependent cellular cytotoxicity (ADCC) and antibody‐dependent cellular phagocytosis (ADCP) activity in ex vivo models
-
Other Disease-Related Content
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Jonas K, et al.
Intention to use long‐acting PrEP among 4960 heterosexual women and men in 20 European countries: results from the PROTECT survey
Wang H, et al.
Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis
Zimmermann H, et al.
Preparing for long‐acting PrEP delivery: provider preferences for the provision of long‐acting PrEP differ between MSM and heterosexual individuals in Europe
-
Cabotegravir Treatment
Cabello A, et al.
Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long‐acting (LA) CAB+RPV administration out of HIV units: the IMADART study
Elias A, et al.
Re‐suppression regimens and outcomes after virological failure in randomized controlled trials and real‐world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)
Fernández A, et al.
Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine
Hessamfar M, et al.
Use of long‐acting cabotegravir and rilpivirine in a real‐life setting: 12‐month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH‐NA Cohort‐France
Abstract available on HIV Glasgow website
Hidalgo‐Tenorio C, et al.
Results at month 7 of CABO‐CHANCE study: real‐world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long‐acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)
Smuk M, et al.
Virological failure rate and emergent resistance in real‐world studies evaluating long‐acting cabotegravir and rilpivirine in people with baseline viral suppression
-
Dolutegravir-based Regimens
Cordova E, et al.
Efficacy of dolutegravir plus lamivudine in treatment‐naïve people living with HIV without baseline drug‐resistance testing available: 48‐week results from the randomised D2ARLING study
de Lagarde Sebastian M, et al.
Long‐term efficacy and safety of dolutegravir/lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial ‐ GESIDA 11820
Degroote S, et al.
RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
Figueroa MI, et al.
Comparable efficacy and safety of dolutegravir/lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study
Garcia‐Fraile L, et al.
Changes in patient‐reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO‐DOBLE randomized clinical trial
Miro JA, et al.
Efficacy and safety of dolutegravir (DTG)‐based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): a single‐arm clinical trial (DTG‐SOT)
Abstract available on HIV Glasgow website
Ryan R, et al.
Dolutegravir‐based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV‐negative controls
Voit F, et al.
Evaluating the cardiovascular risk and the achievement of target levels in low‐density lipoprotein cholesterol in PLWH: insights from the DUALIS study
Abstract available on HIV Glasgow website
Wolf E, et al.
Mental health in people with HIV (PWH): patient‐reported outcomes in the DUALIS study
Abstract available on HIV Glasgow website
-
Other Disease-Related Content
Allavena C, et al.
Comparison of four frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study)
Abstract available on HIV Glasgow website
Deb S, et al.
The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study
Abstract available on HIV Glasgow website
Sukumaran L, et al.
The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3‐5 year period
Abstract available on HIV Glasgow website
-
-
Plain Language Summaries
